Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results

We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corcept Therapeutics Inc. (NASDAQ:CORT) was one of the best performers on Thursday.

Corcept Therapeutics extended its winning streak to a third consecutive day on Thursday, jumping 13.74 percent to close at $41.30 apiece as investors cheered clinical results from its late-stage study of drug candidate, relacorilant, in patients with platinum-resistant ovarian cancer.

In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that relacorilant, when combined with nab-paclitaxel chemotherapy, showed a 35 percent reduction of death risks in patients, as compared with those treated with nab-paclitaxel alone, during the third phase of its clinical trial. The therapy was also able to cut disease progression by 30 percent.

Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results

The median overall survival for patients receiving relacorilant was 16 months, as compared with 11.9 months for those receiving nab-paclitaxel alone.

Corcept Therapeutics Inc. (NASDAQ:CORT) said that relacorilant, in combination with nab-paclitaxel, was well-tolerated, consistent with its known safety profile.

The trial enrolled a total of 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel, or nab-paclitaxel alone.

Corcept Therapeutics Inc. (NASDAQ:CORT) said that complete results from the study are set to be announced at an upcoming medical conference.

While we acknowledge the risk and potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CORT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.